Evolv GLP-1, Evolv GLP-1 Biomimetic, Evolv GLP-1 Oral Peptide Case Investigation

Chimicles Schwartz Kriner & Donaldson-Smith LLP is investigating potential class action claims on behalf of those who purchased Evolv GLP-1, which is sold by BioDrive, Inc. as an oral weight loss supplement. Evolv GLP-1 is marketed as a bioengineered peptide called EV1 Peptide, that the company claims activates the body’s GLP-1 and GIP pathways, the same pathways targeted by prescription weight-loss drugs. The company’s marketing states that the product “delivers the full power of GLP-1 naturally” and is “designed to naturally activate GLP-1 in the body for extended periods.” One cofounder has publicly described it as “a GLP-1 and GIP receptor agonist oral supplement.” Chimicles Schwartz Kriner & Donaldson-Smith LLP is investigating allegations of whether those marketing claims about Evolv are supported, and whether consumers paid for a supplement that did not do what the sellers claimed it would do.

If you purchased Evolv GLP-1, or any other weight-loss supplements, please contact our attorneys by completing the form below to learn more about our ongoing investigation and your potential legal rights.

Quick Facts

If you purchased Evolv GLP-1

Useful to gather:

• Receipts, order confirmations, or card statements showing dates and amounts
• Whether you were enrolled in a recurring subscription, and whether you could cancel
• Screenshots of the advertising you saw before purchasing
• The bottle and label, if you still have it